KRAS-targeted cancer vaccine shows promise Final results from the AMPLIFY-201 phase 1 trial highlight durable T cell responses and prolonged survival in patients with colorectal and pancreatic cancer.

https://www.drugdiscoverynews.com/kras-targeted-vaccine-shows-promise-16685